HUP9702388A2 - Növekedésihormon-kibocsátást serkentő vegyületek és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Növekedésihormon-kibocsátást serkentő vegyületek és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP9702388A2 HUP9702388A2 HU9702388A HUP9702388A HUP9702388A2 HU P9702388 A2 HUP9702388 A2 HU P9702388A2 HU 9702388 A HU9702388 A HU 9702388A HU P9702388 A HUP9702388 A HU P9702388A HU P9702388 A2 HUP9702388 A2 HU P9702388A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- growth hormone
- contg
- pharmaceuticals
- hormone releasing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 230000003578 releasing effect Effects 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fodder In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A jelen találmány tárgyát új, a növekedési hőrmőn hiányából eredőbetegségek gyógykezelésére szőlgáló vegyületek és azőkat tartalmazógyógyszerkészítmények képezik. Az (I) általánős képletű vegyületek az enzimek fehérjebőntó hatásávalszemben főkőzőtt mértékű ellenálló képességet műtatnak, mert azőkban atemészetes amid kötéseket nem természetes amid kötést űtánzóakkalhelyettesítették. A találmány szerinti vegyületek fehérjebőntóhatással szembeni főkőzőtt ellenálló-képességet műtatnak éscsökkentett méretűek, így azők biőlógiai hőzzáférhetősége jó. ŕ
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK9995 | 1995-01-27 | ||
DK10095 | 1995-01-27 | ||
DK108495 | 1995-09-28 | ||
DK108395 | 1995-09-28 | ||
DK137295 | 1995-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9702388A2 true HUP9702388A2 (hu) | 1998-04-28 |
HUP9702388A3 HUP9702388A3 (en) | 1999-01-28 |
Family
ID=27512745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9702388A HUP9702388A3 (en) | 1995-01-27 | 1996-01-26 | Compounds with growth hormone releasing properties and pharmaceuticals contg. them |
Country Status (20)
Country | Link |
---|---|
US (2) | US6013658A (hu) |
EP (1) | EP0805816B1 (hu) |
JP (1) | JP4073952B2 (hu) |
CN (1) | CN1225471C (hu) |
AR (1) | AR003108A1 (hu) |
AT (1) | ATE272069T1 (hu) |
AU (1) | AU705744B2 (hu) |
CA (1) | CA2211381C (hu) |
CZ (1) | CZ238197A3 (hu) |
DE (1) | DE69633003T2 (hu) |
HU (1) | HUP9702388A3 (hu) |
ID (1) | ID18218A (hu) |
IL (1) | IL116923A (hu) |
MX (1) | MX9705710A (hu) |
MY (1) | MY113488A (hu) |
NO (1) | NO973446L (hu) |
PL (1) | PL186511B1 (hu) |
TW (1) | TW482767B (hu) |
UA (1) | UA55381C2 (hu) |
WO (1) | WO1996022997A1 (hu) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
ATE272069T1 (de) | 1995-01-27 | 2004-08-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
EP0869974B1 (en) * | 1995-12-22 | 2009-03-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
DE69734215T2 (de) * | 1996-07-22 | 2006-06-29 | Novo Nordisk A/S | Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften |
EP1005484A1 (en) | 1997-06-20 | 2000-06-07 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US6127341A (en) * | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
JP4382279B2 (ja) | 1998-01-16 | 2009-12-09 | サファイア セラピューティクス,インコーポレイティド | 成長ホルモン放出特性を有する化合物 |
US6506782B1 (en) * | 1998-02-27 | 2003-01-14 | Athena Neurosciences, Inc. | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US6380184B1 (en) | 1998-10-28 | 2002-04-30 | Bristol-Myers Squibb Co. | Benzoazepines and analogs thereof useful as growth hormone secretagogues |
EP1126833A4 (en) * | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
AU759022B2 (en) | 1999-02-18 | 2003-04-03 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
CA2401749A1 (en) * | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
AU5959201A (en) | 2000-05-11 | 2001-11-20 | Bristol Myers Squibb Co | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
CA2410972A1 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
WO2003002122A1 (en) * | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
AU2013205089B2 (en) * | 2004-03-15 | 2013-12-19 | Janssen Pharmaceutica, N.V. | Novel compounds as opioid receptor modulators |
SI2298744T1 (sl) | 2004-03-15 | 2013-10-30 | Janssen Pharmaceutica N.V. | Modulatorji opioidnega receptorja |
AU2012202459B2 (en) * | 2004-03-15 | 2014-06-12 | Janssen Pharmaceutica, N.V. | Novel compounds as opioid receptor modulators |
US20090149512A1 (en) * | 2004-05-14 | 2009-06-11 | Novo Nordisk A/S | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases |
AU2005277389A1 (en) | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
WO2006084033A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
JP5384933B2 (ja) * | 2005-03-14 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | オピオイド調節物質の製造方法 |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
JP2010518090A (ja) | 2007-02-09 | 2010-05-27 | トランザイム・ファーマ,インコーポレイテッド | 大環状グレリン受容体修飾因子およびその使用方法 |
EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
JP2016503394A (ja) | 2012-10-26 | 2016-02-04 | エヌライフ、セラピューティックス、ソシエダッド、リミターダNlife Therapeutics, S.L. | 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法 |
US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
EP3116503A4 (en) * | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
WO2021086904A1 (en) | 2019-10-29 | 2021-05-06 | Aerpio Pharmaceuticals, Inc. | Small molecule activators of tie-2 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017423A1 (en) * | 1993-12-23 | 1995-06-29 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5618792A (en) * | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
ATE272069T1 (de) * | 1995-01-27 | 2004-08-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
US5559128A (en) * | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
EP0869974B1 (en) | 1995-12-22 | 2009-03-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
-
1996
- 1996-01-26 AT AT96900550T patent/ATE272069T1/de not_active IP Right Cessation
- 1996-01-26 MY MYPI96000291A patent/MY113488A/en unknown
- 1996-01-26 ID IDP960190A patent/ID18218A/id unknown
- 1996-01-26 CN CNB961921846A patent/CN1225471C/zh not_active Expired - Fee Related
- 1996-01-26 EP EP96900550A patent/EP0805816B1/en not_active Expired - Lifetime
- 1996-01-26 CZ CZ972381A patent/CZ238197A3/cs unknown
- 1996-01-26 IL IL11692396A patent/IL116923A/xx not_active IP Right Cessation
- 1996-01-26 AU AU44315/96A patent/AU705744B2/en not_active Ceased
- 1996-01-26 UA UA97073973A patent/UA55381C2/uk unknown
- 1996-01-26 MX MX9705710A patent/MX9705710A/es active IP Right Grant
- 1996-01-26 HU HU9702388A patent/HUP9702388A3/hu unknown
- 1996-01-26 WO PCT/DK1996/000045 patent/WO1996022997A1/en not_active Application Discontinuation
- 1996-01-26 AR ARP960101177A patent/AR003108A1/es unknown
- 1996-01-26 DE DE69633003T patent/DE69633003T2/de not_active Expired - Fee Related
- 1996-01-26 CA CA002211381A patent/CA2211381C/en not_active Expired - Fee Related
- 1996-01-26 PL PL96321590A patent/PL186511B1/pl not_active IP Right Cessation
- 1996-01-26 JP JP52255996A patent/JP4073952B2/ja not_active Expired - Fee Related
- 1996-02-27 TW TW085102211A patent/TW482767B/zh not_active IP Right Cessation
-
1997
- 1997-07-17 US US08/897,239 patent/US6013658A/en not_active Expired - Fee Related
- 1997-07-25 NO NO973446A patent/NO973446L/no unknown
-
1999
- 1999-11-19 US US09/443,993 patent/US6350767B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0805816B1 (en) | 2004-07-28 |
AU705744B2 (en) | 1999-06-03 |
US6350767B1 (en) | 2002-02-26 |
PL186511B1 (pl) | 2004-01-30 |
ATE272069T1 (de) | 2004-08-15 |
AR003108A1 (es) | 1998-07-08 |
MX9705710A (es) | 1997-10-31 |
MY113488A (en) | 2002-03-30 |
DE69633003D1 (de) | 2004-09-02 |
IL116923A (en) | 2000-09-28 |
AU4431596A (en) | 1996-08-14 |
US6013658A (en) | 2000-01-11 |
ID18218A (id) | 1998-03-19 |
DE69633003T2 (de) | 2005-08-18 |
NO973446L (no) | 1997-09-26 |
CA2211381A1 (en) | 1996-08-01 |
HUP9702388A3 (en) | 1999-01-28 |
IL116923A0 (en) | 1996-05-14 |
CN1176645A (zh) | 1998-03-18 |
CZ238197A3 (en) | 1997-12-17 |
JP4073952B2 (ja) | 2008-04-09 |
UA55381C2 (uk) | 2003-04-15 |
EP0805816A1 (en) | 1997-11-12 |
CA2211381C (en) | 2009-05-19 |
TW482767B (en) | 2002-04-11 |
PL321590A1 (en) | 1997-12-08 |
WO1996022997A1 (en) | 1996-08-01 |
NO973446D0 (no) | 1997-07-25 |
CN1225471C (zh) | 2005-11-02 |
JPH11500107A (ja) | 1999-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9702388A2 (hu) | Növekedésihormon-kibocsátást serkentő vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
HUP0203084A2 (en) | Use of baff receptor (bcma) as an immunoregulatory agent | |
ATE332702T1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
HUP0103598A2 (hu) | Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra | |
BRPI0507822A (pt) | método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna | |
NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
MX9605940A (es) | Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
DE59407237D1 (de) | Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems | |
ATE263571T1 (de) | Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen | |
ATE76570T1 (de) | Mittel zur haarbehandlung. | |
MX9501848A (es) | Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos. | |
SE9704693D0 (sv) | Method of the prophylactic treatment of mastitis | |
ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
NO172043C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater | |
RU94045930A (ru) | Белки, днк, вектор, клетка, способы получения и очистки белка, фармацевтическая композиция | |
GB2311724A (en) | New applications of lysozyme dimer | |
ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
DE69334087D1 (de) | Arzneimittelzusammensetzung enthaltend TCF-II | |
RU95110774A (ru) | Олигонуклеотиды, терапевтические композиции, применение композиций | |
EP0516845A4 (en) | NEW MEGAKARYOCYTIC COLONY-STIMULATING FACTOR AND METHOD FOR THE PRODUCTION THEREOF. | |
FR2658190B1 (fr) | Esters d'aminoacides de l'hydroquinone, leur procede de preparation et compositions pharmaceutiques ou cosmetiques les contenant. | |
DE69828876D1 (de) | Zusammensetzung für die behandlung von erkrankungen, die mit apoptose einhergehen | |
ATE203680T1 (de) | Konjugat zur behandlung von entzündungserkrankungen | |
ATE317905T1 (de) | Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: SAPPHIRE THERAPEUTICS, INC., US Free format text: FORMER OWNER(S): NOVO NORDISK A/S, DK |
|
FD9A | Lapse of provisional protection due to non-payment of fees |